Quantcast

Latest Psoriasis Stories

Man With Hair-Loss Disease Gets New Growth Using Arthritis Drug
2014-06-19 15:21:48

Gerard LeBlond for redorbit.com - Your Universe Online Doctors at Yale University administered treatment for a non curable disease (alopecia universalis) in a 25-year-old man that left him without any hair. After the treatment, the man grew a full head of hair, eyebrows, eyelashes, armpit, facial and other hair on various parts of his body. His disease had not been previously treated and this was the first reported case with successful results. “The results are exactly what we...

2014-06-18 08:28:40

~Expert panel shares tips, encouraging patients to take a 360° approach to managing their disease and to not give up until they're satisfied~

2014-06-18 08:28:09

-- Latest psychological research reveals rosacea redness creates negative first impressions putting sufferers at a disadvantage -- Rosacea remains under-diagnosed, yet diagnosis is a critical first step to better symptom control THORNHILL, ON, June 18 2014 /CNW/ - Sex and the City actress Cynthia Nixon today spoke out about her experience of rosacea in support of 'Act on Red', a new global disease awareness program urging fellow sufferers to seek help for their...

2014-06-17 23:14:39

MedicationDiscountCard.com now aims to help those suffering from psoriasis afford needed prescriptions. Houston, TX (PRWEB) June 17, 2014 Psoriasis is an autoimmune disease that is most often associated with dry, red patches on the skin—but this disease is not just skin deep. It can increase a victim’s risk for cardiovascular disease, some cancers, certain types of arthritis, or ulcerative colitis. Psoriasis is referred to as a genetic disease, since it occurs in families and is not...

2014-06-17 08:28:28

Previously released interim results from the trial showed positive safety and efficacy; 300 patients with moderate to severe disease were enrolled in the study PETACH TIKVA, Israel, June 17, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has finalized enrollment in its Phase II/III trial of CF101 for the treatment...

2014-06-11 16:27:22

Phase 3 Program Underway to Further Assess Brodalumab as Potential Treatment for People Living With Psoriatic Arthritis THOUSAND OAKS, Calif. and LONDON, June 11, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM). These data will also be presented at the 2014 European League Against Rheumatism (EULAR)...

2014-06-11 04:21:56

- Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were...

2014-06-09 08:28:15

- Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded PETACH TIKVA, Israel, June 9, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc., has issued an update on its clinical developments and strategic...

2014-06-05 23:12:01

ResearchMoz.us includes new market research report "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Albany,New York (PRWEB) June 05, 2014 Researchmoz presents this most up-to-date research on "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation". The report focuses primarily on quantitative market metrics in order to characterize the growth and...

2014-06-01 23:01:09

LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas, TX (PRWEB) June 01, 2014 Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related